Dual inhibition of AKT and ERK1/2 pathways restores the expression of progesterone Receptor-B in endometriotic lesions through epigenetic mechanisms
Molecular and Cellular Endocrinology · 2024-10 · 592 · 112290
DOI: 10.1016/j.mce.2024.112290 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular and Cellular Endocrinology, 2024-10. Verfasst von Sudipta Dutta und 3 weiteren Autor:innen. Beteiligte Einrichtung: Reproductive Endocrinology and Cell Signaling Laboratory, Department of Integrative Biosciences, College of Veterinary Medicine and Biomedical Scienc…. Hauptthemen laut MEDLINE: Receptors, Progesterone, Endometriosis, Epigenesis, Genetic, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: National Institute of Child Health and Human Development, NICHD.
Abstract (Originalsprache)
Endometriosis is an estrogen-dependent and progesterone-resistant gynecological inflammatory disease of reproductive-age women. Progesterone resistance, loss of progesterone receptor -B (PR-B) in the stromal cells of the endometrium, is one of the hallmarks of endometriosis and a major contributing factor for infertility in endometriosis patients. Loss of PR-B in the stromal cells of the endometriotic lesions poses resistance to the success of progesterone-based therapy. The working hypothesis is that PR-B is hypermethylated and epigenetically silenced, and inhibition of AKT and ERK1/2 pathways will decrease the hypermethylation, reverse the epigenetic silencing, and restore the expression of PR-B via DNA methylation and histone modification mechanisms in the endometriotic lesions. The objectives are to (i) determine the effects of dual inhibition of AKT and ERK1/2 pathways on the expression of PR-B and DNA methylation and histone modification protein machinery in the endometriotic lesions and (ii) identify the underlying epigenetic mechanisms of PR-B restoration in the endometriotic lesions. The results indicate that dual inhibition of AKT and ERK1/2 pathways decreases the hypermethylation, reverses the epigenetic silencing, and restores the expression of PR-B via DNA methylation and H3K9 and H3K27 methylation mechanisms in the endometriotic lesions or endometriotic stromal cells of human origin. These results support the novel concept that restored expression of PR-B in the endometriotic lesions and endometrium may improve the clinical outcome of progesterone therapy in endometriosis patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Reproductive Endocrinology and Cell Signaling Laboratory, Department of Integrative Biosciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, Texas, 77843, College Station, USA.
- Reproductive Endocrinology and Cell Signaling Laboratory, Department of Integrative Biosciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, Texas, 77843, College Station, USA. Electron…
Förderung
- National Institute of Child Health and Human Development
- NICHD
Zitieren
APA
Dutta, S., Lee, J., Banu, S. K., & Arosh, J. A. (2024). Dual inhibition of AKT and ERK1/2 pathways restores the expression of progesterone Receptor-B in endometriotic lesions through epigenetic mechanisms. Molecular and Cellular Endocrinology, 592, 112290. https://doi.org/10.1016/j.mce.2024.112290
Vancouver
Dutta S, Lee J, Banu SK, Arosh JA. Dual inhibition of AKT and ERK1/2 pathways restores the expression of progesterone Receptor-B in endometriotic lesions through epigenetic mechanisms. Molecular and Cellular Endocrinology. 2024;592:112290. doi:10.1016/j.mce.2024.112290
BibTeX
@article{Dutta2024,
author = {Dutta, Sudipta and Lee, JeHoon and Banu, Sakhila K and Arosh, Joe A},
title = {Dual inhibition of AKT and ERK1/2 pathways restores the expression of progesterone Receptor-B in endometriotic lesions through epigenetic mechanisms},
journal = {Molecular and Cellular Endocrinology},
year = {2024},
volume = {592},
pages = {112290},
doi = {10.1016/j.mce.2024.112290}
}
EUVIMED